Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

NCT07564401 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07564401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07564401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 16, 2026
Completion date
March 3, 2031
Enrollment
80 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer (es-sclc)